A member of stem cell company Athersys Inc.’s (NASDAQ: ATHX) board of directors has resigned.
As of Sept. 9, Michael Sheffery, a general partner with New York-based venture firm OrbiMed Advisors, no longer is a member of Athersys board, according to a regulatory document the company filed with the Securities and Exchange Commission. Athersys is one of OrbiMed’s portfolio companies.
Sheffery’s decision to resign was not the result of a disagreement with Athersys’ management, according to the SEC filing. However, a company spokesman declined to say why Sheffery resigned.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Sheffery had served on the board since June 2007 and was a member of its compensation and nomination committees.
In July, Cleveland’s Athersys reported encouraging results from a small Phase 1 trial to determine the safety and maximum dose of its MultiStem therapy for heart attack patients.
